Politico December 13, 2024
Erin Schumaker and Daniel Payne with Carmen Paun

THE NEXT CURES

Psychedelics could offer relief to doctors who provided frontline care during the pandemic and later became depressed.

That’s according to a small new study published in JAMA Network Open this month.

Inside the study: Of the 30 participants in the double-blind, randomized trial, half received two preparation sessions; one dose of synthetic psilocybin, also known as magic mushrooms; and three follow-up counseling sessions with a trained facilitator. The other half, the control group, received the same sequence of sessions, except a placebo was swapped for the psilocybin.

While both groups saw their depression symptoms improve, participants in the psilocybin group had faster, bigger and more long-lasting drops in their depression scores.

Because the study was small, its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID, Trends
The U.S. Government and the World Health Organization - 2
Moderna gets $590M from US government for bird flu vaccine
CDC: Flu activity remains high, COVID-19 increasing while RSV peaks
As H5N1 Is Detected In San Francisco, A Panel Discusses Next Steps
Donald Trump’s first steps on healthcare: Inaugural remarks, leaving the WHO, and more

Share This Article